Alzheimer’s in the U.S.

Alzheimer’s 2100

Alzheimer’s drug market

SYMPTOM PREVENTIVE

0

Multiple attempts

Alzheimer's Drug From Pfizer, J&J Fails in Late-Stage Trial

Lilly Halts Alzheimer's Drug Trial

Glaxo’s Avandia Fails to Benefit Alzheimer’s Patients

$10B

PREVENTIVEDRUG MARKET

$1B

FAILED DRUGS

The best time to treat Alzheimer’s

Disease is likely to be before

memory loss and tissue

destruction occurs…

NORMAL BRAIN ALZHEIMER’S

Alter the trajectory

disease progressio

n

time

Current standard of diagnosis

Preventive

3 years

Our technology

EYETRACKING

NEWIMAGE

CHANGEDETECTION

3YEARS

EARLIER

Alzheimer’s conversion

0 100

0%of high scorers

99.9%of low scorers

20,000requiredpatients

100new clinical

trials each year

1Phase IV

approved therapy

Strategy

the Alzheimer’s diagnostic

Patents filed and pending

Worldwide license

Pilot discussions

today

Team

Elli KaplanCEO

Colin McDonaldCMO

Dr. Stuart Zola

Dr. Beth Buffalo

Dr. Eugene Agichtein

Scientific Advisory

Next steps

Business development

Seed capital